Literature DB >> 14715379

Within-person variability of urinary 6beta-hydroxycortisol to urinaryl ratios in Caucasian women.

Zhi Chen1, Lisa A Dunning, Kristin E Anderson, Jordan L Holtzman, Wei Zheng.   

Abstract

Cortisol is metabolized to 6beta-hydroxycortisol by human cytochrome p450-3A4 (CYP3A4), an important enzyme involved in the metabolism of a variety of exogenous and endogenous compounds. Both cortisol and 6beta-hydroxycortisol are excreted in urine, and the ratio of these steroids has been proposed as an indicator of CYP3A4 activity. We evaluated within-person variability of this biomarker in 10 healthy Caucasian women, aged 23-58 years. Each study participant was asked to provide a fasting morning urine sample once a week consecutively for 8 weeks. Urinary cortisol and 6beta-hydroxycortisol were determined by immunoassay kits purchased from the DiaSorin (Stillwater, MN) and the Stabiligen (Nancy, France), respectively. The coefficients of variation (CV) of urinary 6beta-hydroxycortisol to cortisol ratios from study participants ranged from 16.7 to 51.4% (mean, 31.1%) over the study period. The level of the ratio measured in any single urine sample was correlated reasonably well with the average of the ratios over the 8-week study period from the same woman, with the mean correlation coefficient of 0.79. These results indicated that urinary 6beta-hydroxycortisol to cortisol ratios measured in a spot urine sample may reflect the level of this biomarker over a relatively longer time period in Caucasian women, and thus, it can be used in epidemiologic studies as a biomarker to evaluate the association between CYP3A4 activity and disease risk.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14715379     DOI: 10.1016/j.steroids.2003.10.004

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  7 in total

1.  Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics.

Authors:  F T Aweeka; C Hu; L Huang; B M Best; A Stek; P Lizak; S K Burchett; J S Read; H Watts; M Mirochnick; E V Capparelli
Journal:  HIV Med       Date:  2014-11-18       Impact factor: 3.180

2.  Canine urinary lactate and cortisol metabolites in hypercortisolism, nonadrenal disease, congestive heart failure, and health.

Authors:  Arnon Gal; Ryan Fries; Saki Kadotani; Alexander V Ulanov; Zhong Li; J Catharine Scott-Moncrieff; Richard K Burchell; Nicolas Lopez-Villalobos; Yigal Petreanu
Journal:  J Vet Diagn Invest       Date:  2022-06-03       Impact factor: 1.569

3.  Changes in the Choroidal Thickness following Intravitreal Bevacizumab Injection in Chronic Central Serous Chorioretinopathy.

Authors:  Yoo-Ri Chung; Su Jeong Lee; Ji Hun Song
Journal:  J Clin Med       Date:  2022-06-13       Impact factor: 4.964

4.  Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.

Authors:  Rosa F Yeh; Naser L Rezk; Angela D M Kashuba; Julie B Dumond; Hiba L Tappouni; Hsiao-Chuan Tien; Ya-Chi Chen; Manoli Vourvahis; Amanda L Horton; Susan A Fiscus; Kristine B Patterson
Journal:  Antimicrob Agents Chemother       Date:  2009-03-23       Impact factor: 5.191

Review 5.  A Physiology-Based Pharmacokinetic Framework to Support Drug Development and Dose Precision During Therapeutic Hypothermia in Neonates.

Authors:  Anne Smits; Pieter Annaert; Steven Van Cruchten; Karel Allegaert
Journal:  Front Pharmacol       Date:  2020-05-13       Impact factor: 5.810

6.  Studies on CYP3A activity during the menstrual cycle as measured by urinary 6β-hydroxycortisol/cortisol.

Authors:  Helena Bergström; Anna Lindahl; Anna Warnqvist; Ulf Diczfalusy; Lena Ekström; Linda Björkhem-Bergman
Journal:  Pharmacol Res Perspect       Date:  2021-12

7.  Study of the Urinary Ratio of 6 beta-Hydroxycortisol/Cortisol as a Biomarker of CYP3A4 Activity in Egyptian Patients with Chronic Liver Diseases.

Authors:  Ehab S Eldesoky; Sherif I Kamel; Ahlam M Farghaly; Madiha Y Bakheet; Mohsen A Hedaya; Jean-Pascal Siest
Journal:  Biomark Insights       Date:  2007-02-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.